In this review, we update the recent clinically relevant aspects of the pathobiology of KRAS-mutant non-small cell lung cancer (NSCLC), mainly focusing on tumor heterogeneity, therapeutic implications, and new treatment opportunities. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.